WHO ICTRP trial
Dose Escalation of DF1001 in Patients With Advanced Solid Tumors, and Expansion…
CTIS2023-503291-24-00 · EU Clinical Trials Information System · Recruiting
Key facts
| Trial ID | CTIS2023-503291-24-00 |
|---|---|
| Public title | Dose Escalation of DF1001 in Patients With Advanced Solid Tumors, and Expansion in Selected Indications |
| Scientific title | A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications - DF1001-001 |
| Primary sponsor | Dragonfly Therapeutics Inc. |
| Registry | EU Clinical Trials Information System |
| Recruitment status | Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): Yes Therapeutic exploratory (Phase II): Yes Therapeutic confirmatory - (Phase III): No Therapeutic use - (Phase IV): No |
| Countries | Korea, Republic of;United States;Belgium;Denmark;France;Netherlands |
| Conditions | Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications MedDRA version: 21.1Level: LLTClassification code: 10065252Term: Solid tumor Class: 10029104;Therapeutic area: Diseases [C] - Neoplasms [C04] |
| Interventions | Product Name: Abraxane 5 mg/ml powder for dispersion for infusion., Product Code:PRD9254303, Pharmaceutical Form: DISPERSION FOR INFUSION, Other descriptive name: , Strength: , Product Name: DF1001, Product Code:PRD8217878, Pharmaceutical… |
| Registration date | Feb 10, 2024 |
| Target size | 388 |
| Secondary IDs | NCT04143711;2019-004706-10 |
| Registry page | euclinicaltrials.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: